Cullinan Therapeutics, Inc. CGEM 深 滬
已收盤 04-02 16:00:00 美东时间
14.43
+0.490
+3.52%
華盛通- 最 高14.62
- 今 開13.51
- 成交量 114.96万股
- 最 低 13.51
- 昨 收 13.94
- 總市值 8.73亿
- 52周最高 16.74
- 市盈率 靜 --
- 換手率 1.90%
- 52周最低 5.68
- 委 比 -54.77%
- 總股本 6052.61万
- 歷史最高 59.85
- 量 比 1.54
- 振 幅 7.96%
- 歷史最低 5.68
- 每 手 1
- 風險率 2.50%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 甲骨文绩后分歧大！小摩上调评级至"超配"，目标价缺降至210美元；科尔士百货、AVAV、Blend Labs、Domo遭多家大行下调评级
今日重点评级关注：LUCID CAPITAL MARKETS：上调INmune Bio评级至"买入" 目标价从2美元升至9美元；Clear Street：维持MoonLake Immunotherapeutics Class A"买入"评级，目标价从45美元升至70美元
03-12 12:34
Wedbush Maintains Outperform on Cullinan Therapeutics, Raises Price Target to $36
Wedbush analyst Robert Driscoll maintains Cullinan Therapeutics (NASDAQ:CGEM) with a Outperform and raises the price target from $34 to $36.
03-11 20:53
Cullinan Therapeutics: Q4 Earnings Insights
Cullinan Therapeutics (NASDAQ:CGEM) just disclosed its Q4 earnings on Tuesday, ...
03-11 05:29
Cullinan Therapeutics Q4 EPS $(0.77) Beats $(0.82) Estimate
Cullinan Therapeutics (NASDAQ:CGEM) reported quarterly losses of $(0.77) per share which beat the analyst consensus estimate of $(0.82) by 6.1 percent. This is a 5.48 percent decrease over losses of $(0.73) per share
03-10 19:17
美股大行评级 | 潜在涨幅1226.53%！RenovoRx获Ascendiant Capital升目标价至13美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持RenovoRx"买入"评级，目标价从12.5美元升至13美元；Lake Street：维持Insight Molecular"买入"评级，目标价从8美元升至12美元
02-18 16:48
Citigroup Initiates Coverage On Cullinan Therapeutics with Buy Rating, Announces Price Target of $33
Citigroup analyst Samantha Semenkow initiates coverage on Cullinan Therapeutics (NASDAQ:CGEM) with a Buy rating and announces Price Target of $33.
02-17 23:05
美股大行评级 | 高露洁棕榄、再生元制药、伊士曼化工、威瑞森、Ameris、丘奇＆德怀特等获多家大行上调目标价
今日重点评级关注：Benchmark：维持Charter Communications"买入"评级，目标价从425美元升至455美元；BTIG：维持LifeStance Health Gr"买入"评级，目标价从10美元升至11美元
02-03 09:06
Guggenheim Initiates Coverage On Cullinan Therapeutics with Buy Rating, Announces Price Target of $30
Guggenheim analyst Brad Canino initiates coverage on Cullinan Therapeutics (NASDAQ:CGEM) with a Buy rating and announces Price Target of $30.
02-02 22:33
美股大行评级 | 潜在涨幅197.4%！奥麦罗制药获HC Wainwright升目标价至40美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持奥麦罗制药"买入"评级，目标价从20美元升至40美元；HC Wainwright & Co.：维持Cullinan Therapeutics"买入"评级，目标价从26美元升至27美元
01-09 20:22
HC Wainwright & Co. Maintains Buy on Cullinan Therapeutics, Raises Price Target to $27
HC Wainwright & Co. analyst Robert Burns maintains Cullinan Therapeutics (NASDAQ:CGEM) with a Buy and raises the price target from $26 to $27.
01-09 00:42
